Literature DB >> 1707461

Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts.

P L Tan1, S Farmiloe, S Yeoman, J D Watson.   

Abstract

A number of fibroblastoid synovial cell lines have been established from rheumatoid joints. These cell lines were shown to express the interleukin 6 (IL-6) gene constitutively, and exposure of these cells to 5 ng/ml of recombinant human interleukin 1 beta (IL-1 beta) increased IL-6 gene expression. Other recombinant human lymphokines, namely interferon-gamma, tumor necrosis factor-alpha, and granulocyte-macrophage colony stimulating factor had no enhancing effect on IL-6 gene expression. Dexamethasone added to the cultures at 10(-7) M concentration suppressed the constitutive expression of the IL-6 gene. At a concentration of 10(-5) M, dexamethasone partially suppressed the IL-1 enhanced expression of IL-6. The IL-6 gene probe also hybridized to RNA from unfractionated synovial fluid cells, peripheral blood T cells and non-T cells but not Epstein-Barr virus transformed peripheral blood B cells of patients with rheumatoid arthritis. Our results suggest that in rheumatoid arthritis, synovial fibroblasts actively participate in joint inflammation by lymphokine production. The coexpression of both IL-1 and IL-6 by one synovial fibroblast line suggests a mechanism for the perpetuation of synovitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1707461

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Production of interleukin-6 by synovial fibroblasts in rheumatoid arthritis.

Authors:  H Baumann; I Kushner
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

2.  Effects of low-dose-gamma rays on the immune system of different animal models of disease.

Authors:  Noriko Shimura; Shuji Kojima
Journal:  Dose Response       Date:  2014-04-23       Impact factor: 2.658

Review 3.  Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.

Authors:  Z Szekanecz; A E Koch; S L Kunkel; R M Strieter
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

4.  Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy.

Authors:  S Ohshima; Y Saeki; T Mima; M Sasai; K Nishioka; H Ishida; M Shimizu; M Suemura; R McCloskey; T Kishimoto
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

5.  Evaluation of interleukin-6 in rheumatoid arthritis as an activity criterion.

Authors:  T Sentürk; G Kinikli; M Turgay; H Tutkak; M Duman; G Tokgöz
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

6.  Basement membrane proteins in synovial membrane: distribution in rheumatoid arthritis and synthesis by fibroblast-like cells.

Authors:  M Schneider; B Voss; J Rauterberg; M Menke; T Pauly; R K Miehlke; J Friemann; U Gerlach
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 7.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

8.  Effect and mechanism of AR-6 in experimental rheumatoid arthritis.

Authors:  Shi-xue Sun; Yun-man Li; Wei-rong Fang; Peng Cheng; Lifang Liu; Fengwen Li
Journal:  Clin Exp Med       Date:  2009-10-20       Impact factor: 3.984

9.  In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs.

Authors:  Nan Zhang; Patricia R Wardwell; Rebecca A Bader
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

10.  Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis.

Authors:  Qunzhou Zhang; Takayoshi Yamaza; A Paul Kelly; Shihong Shi; Songlin Wang; Jimmy Brown; Lina Wang; Samuel W French; Songtao Shi; Anh D Le
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.